BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H, Benda MA, Sprenger-Mähr H, Winder T, Lhotta K. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. Front Immunol 2021;12:704773. [PMID: 34220867 DOI: 10.3389/fimmu.2021.704773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Alqassieh R, Suleiman A, Abu-Halaweh S, Santarisi A, Shatnawi O, Shdaifat L, Tarifi A, Al-Tamimi M, Al-Shudifat AE, Alsmadi H, Al Sharqawi A, Alnawaiseh H, Anasweh Y, Domaidah FA, Jaber HA, Al-Zarir MR, Bsisu I. Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers. Vaccines (Basel) 2021;9:1223. [PMID: 34835153 DOI: 10.3390/vaccines9111223] [Reference Citation Analysis]
2 Ai J, Wang J, Liu D, Xiang H, Guo Y, Lv J, Zhang Q, Li J, Zhang X, Li Q, Liang J, Guo X, Feng Y, Liu L, Zhang X, Qin W, Wang X, Rao W, Zhang Q, Tian Q, Zhang Y, Xie F, Jiang S, Yan Y, Qiu Y, Wu H, Hou Z, Zhang N, Zhang A, Ji J, Yang J, Huang J, Zhao Z, Gu Y, Bian L, Zhang Z, Zou S, Ji H, Ge G, Du X, Hou A, Zhu Y, Cong Q, Xu J, Zu H, Wang Y, Yan Z, Yan X, BianBa Y, Ci Q, Zhang L, Yang S, Gao X, Zhong L, He S, Liu C, Huang Y, Liu Y, Xu D, Zhu Q, Xu X, Lv M, Zhang W, Qi X. Safety and immunogenicity of SARS-CoV-2 vaccines in patients with chronic liver diseases (CHESS-NMCID 2101): A multicenter study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01346-X. [PMID: 34942370 DOI: 10.1016/j.cgh.2021.12.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
3 Boedecker-Lips SC, Lautem A, Runkel S, Klimpke P, Kraus D, Keil P, Holtz S, Tomalla V, Marczynski P, Boedecker CB, Galle PR, Koch M, Weinmann-Menke J. Six-Month Follow-Up after Vaccination with BNT162b2: SARS-CoV-2 Antigen-Specific Cellular and Humoral Immune Responses in Hemodialysis Patients and Kidney Transplant Recipients. Pathogens 2022;11:67. [PMID: 35056015 DOI: 10.3390/pathogens11010067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, Song X. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022;7:166. [PMID: 35597779 DOI: 10.1038/s41392-022-01007-w] [Reference Citation Analysis]
5 Gonzalez-Perez M, Montes-Casado M, Conde P, Cervera I, Baranda J, Berges-Buxeda MJ, Perez-Olmeda M, Sanchez-Tarjuelo R, Utrero-Rico A, Lozano-Ojalvo D, Torre D, Schwarz M, Guccione E, Camara C, Llópez-Carratalá MR, Gonzalez-Parra E, Portoles P, Ortiz A, Portoles J, Ochando J. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination. Front Immunol 2022;13:845882. [PMID: 35401504 DOI: 10.3389/fimmu.2022.845882] [Reference Citation Analysis]
6 Jahn M, Korth J, Dorsch O, Anastasiou OE, Krawczyk A, Brochhagen L, van de Sand L, Sorge-hädicke B, Tyczynski B, Witzke O, Dittmer U, Dolff S, Wilde B, Kribben A. Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis. Vaccines 2022;10:327. [DOI: 10.3390/vaccines10020327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Davidovic T, Schimpf J, Abbassi-nik A, Stockinger R, Sprenger-mähr H, Lhotta K, Zitt E. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients. Front Immunol 2022;13:907615. [DOI: 10.3389/fimmu.2022.907615] [Reference Citation Analysis]
8 Davidovic T, Schimpf J, Abbassi-Nik A, Stockinger R, Sprenger-Mähr H, Lhotta K, Zitt E. Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost. Kidney Int 2021;100:1334-5. [PMID: 34656642 DOI: 10.1016/j.kint.2021.10.006] [Reference Citation Analysis]
9 Moss P, Berenbaum F, Curigliano G, Grupper A, Berg T, Pather S. Benefit–Risk Evaluation of COVID-19 Vaccination in Special Population Groups of Interest. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.05.067] [Reference Citation Analysis]
10 Kanai D, Wakui H, Haze T, Azushima K, Kinguchi S, Tsukamoto S, Kanaoka T, Urate S, Toya Y, Hirawa N, Kato H, Watanabe F, Hanaoka K, Hanaoka M, Mitsuhashi H, Yamaguchi S, Ohnishi T, Tamura K. SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan. Clin Exp Nephrol 2022. [PMID: 35751753 DOI: 10.1007/s10157-022-02243-8] [Reference Citation Analysis]
11 D'Amelio R, Asero R, Cassatella MA, Laganà B, Lunardi C, Migliorini P, Nisini R, Parronchi P, Quinti I, Racanelli V, Senna G, Vacca A, Maggi E. Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. Biomedicines 2021;9:1163. [PMID: 34572349 DOI: 10.3390/biomedicines9091163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Notarte KI, Ver AT, Velasco JV, Pastrana A, Catahay JA, Salvagno GL, Yap EPH, Martinez-Sobrido L, B Torrelles J, Lippi G, Henry BM. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci 2022;:1-18. [PMID: 35220860 DOI: 10.1080/10408363.2022.2038539] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop L, Loubet P, Launay O. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect 2021:S1198-743X(21)00566-8. [PMID: 35020589 DOI: 10.1016/j.cmi.2021.09.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 18.0] [Reference Citation Analysis]
14 Calcoen B, Callewaert N, Vandenbulcke A, Kerstens W, Imbrechts M, Vercruysse T, Dallmeier K, Van Weyenbergh J, Maes P, Bossuyt X, Zapf D, Dieckmann K, Callebaut K, Thibaut HJ, Vanhoorelbeke K, De Meyer SF, Maes W, Geukens N. High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium. Viruses 2022;14:1257. [PMID: 35746728 DOI: 10.3390/v14061257] [Reference Citation Analysis]
15 Berar-Yanay N, Freiman S, Shapira M, Saffoury A, Elemy A, Hamze M, Elhaj M, Zaher M, Matanis L, Armaly ZA. Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients. J Clin Med 2021;11:64. [PMID: 35011801 DOI: 10.3390/jcm11010064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
16 Chen JJ, Lee TH, Tian YC, Lee CC, Fan PC, Chang CH. Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis. JAMA Netw Open 2021;4:e2131749. [PMID: 34709385 DOI: 10.1001/jamanetworkopen.2021.31749] [Reference Citation Analysis]
17 Bassi J, Giannini O, Silacci-Fregni C, Pertusini L, Hitz P, Terrot T, Franzosi Y, Muoio F, Saliba C, Meury M, Dellota EA Jr, Dillen JR, Hernandez P, Czudnochowski N, Cameroni E, Beria N, Ventresca M, Badellino A, Lavorato-Hadjeres S, Lecchi E, Bonora T, Mattiolo M, Trinci G, Garzoni D, Bonforte G, Forni-Ogna V, Giunzioni D, Berwert L, Gupta RK, Ferrari P, Ceschi A, Cippà P, Corti D, Lanzavecchia A, Piccoli L. Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS One 2022;17:e0263328. [PMID: 35143540 DOI: 10.1371/journal.pone.0263328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Beilhack G, Monteforte R, Frommlet F, Gaggl M, Strassl R, Vychytil A. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort. Front Immunol 2021;12:780594. [PMID: 34925359 DOI: 10.3389/fimmu.2021.780594] [Reference Citation Analysis]
19 Tillmann FP, Still H, von Landenberg P. Long-term trajectories of SARS-CoV-2 neutralizing antibodies and predictive value of first dose vaccination-induced IgG-antibodies in hemodialysis patients. Int Urol Nephrol 2021. [PMID: 34860338 DOI: 10.1007/s11255-021-03076-2] [Reference Citation Analysis]
20 Prasithsirikul W, Nopsopon T, Phutrakool P, Suwanwattana P, Kantagowit P, Pongpirul W, Jongkaewwattana A, Pongpirul K. ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis. Vaccines (Basel) 2022;10:959. [PMID: 35746567 DOI: 10.3390/vaccines10060959] [Reference Citation Analysis]